Neutrophils in liver diseases: pathogenesis and therapeutic targets


Previously, it was assumed that peripheral neutrophils are a homogeneous population that displays antimicrobial functions. However, recent data have revealed that neutrophils are heterogeneous and are additionally involved in tissue damage and immune regulation. The phenotypic and functional plasticity of neutrophils has been identified in patients with cancer, inflammatory disorders, infections, and other diseases. Currently, neutrophils, with their autocrine, paracrine, and immune modulation functions, have been shown to be involved in liver diseases, including viral hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, liver fibrosis, cirrhosis, liver failure, and liver cancer. Accordingly, this review summarizes the role of neutrophils in liver diseases.


Neutrophils are polymorphonuclear cells that are abundant in peripheral blood and participate in the antimicrobial response and inflammation-induced tissue damage in vivo. The phenotypic and functional plasticity of neutrophils complicates the etiology of liver diseases, from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma (HCC). During liver injury, neutrophils can be recruited rapidly and perform a series of inherent antibacterial functions, including degranulation, reactive oxygen species (ROS) generation, phagocytosis, and the formation of neutrophil extracellular traps (NETs). Meanwhile, neutrophils are also involved in the regulation of the adaptive immune response through direct contact or the production of indirect mediators.1 The multiple functions of neutrophils make them important in the prevention of microbial invasion, tissue injury or repair, regulation of innate and adaptive immunity, and promotion of cellular transformation in liver diseases. Therefore, neutrophils are also considered to act as a “double-edged sword”. This review summarizes the current progress and some critical issues of neutrophils in liver diseases.

The inherent role of neutrophils

Neutrophils are the most abundant leukocytes in peripheral circulation and are well characterized in the host defense against bacteria, fungi, and viruses, even playing a significant role in shaping adaptive immunity.2 Generally, neutrophils have a half-life shorter than one day; however, their half-life can be lengthened to more than 5 days in certain tissues and under certain specific conditions,3 which provides sufficient time for the formation of neutrophil plasticity under a special microenvironment. Granulocyte colony-stimulating factor (G-CSF) is regarded as the major activator of neutrophil mobilization and survival.4 Infiltration of neutrophils is very common in liver tissue. The damage- and pathogen-associated molecular patterns (DAMPs and PAMPs) released from aseptic inflammatory or infected tissue, respectively, are the principal activators of neutrophils. Neutrophil surface receptors (P-selectin glycoprotein ligand 1, L-selectin, CD44, and macrophage antigen 1 (Mac-1)) mediate the adhesion and migration of neutrophils through their interaction with adhesion molecules (E-selectin and P-selectin) and the integrin superfamily (intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs)) expressed on endothelial cells. The migration speed, polarity, and direction of neutrophils are also influenced by other chemoattractants (e.g., complement 5a (C5a), interleukin (IL)-8, and IL-6). Simultaneously, neutrophils are also capable of directly activating Kupffer cells and endothelial cells, resulting in the upregulation of adhesion molecules (ICAM-1 and VCAM-1) and the promotion of cell adhesion.5 Dipeptidase-1, a major adhesion receptor on hepatic endothelial cells, also mediates neutrophil adhesion in an enzyme activity-independent manner.6 Apoptotic neutrophils are eliminated mainly by macrophages, which contributes to localized tissue inflammation. Meanwhile, activated macrophages secrete both G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF) to slow neutrophil apoptosis.7 Neutrophil necrosis leads to the release of harmful proinflammatory chemokines, cytokines, and granule proteins, which might further aggravate local tissue damage.8 Neutrophil necroptosis enhances macrophage efferocytosis through the expression of “eat me signals”.9 Meanwhile, cytokine-activated macrophages are needed to eliminate excess neutrophils and promote inflammatory remission.10

At local damaged sites, neutrophils capture pathogens by direct interaction or through Fc receptors, integrin, and complement receptors. The antibacterial reactions are mainly mediated by phagocytosis and degranulation-containing elastase, lysozyme, myeloperoxidase (MPO), and other defensins. Simultaneously, superoxide anions and ROS are produced during the progression of the respiratory burst.11 Recently, extracellular fibrous structures, named NETs, which include a large amount of extruded DNA, cationic proteins (elastase, cathepsin G, lactoferrin, MPO, and neutrophil gelatinase-associated lipoprotein (NGAL)) from the cytoplasm and granules, have been demonstrated to have the capacity to capture and kill pathogenic microorganisms. NETs carrying NGAL released by neutrophils are regarded as important mediators in the defense against bacterial infection in vivo.12

The defense activities of neutrophils are harmoniously coordinated and regulated, leading to rapid bacterial clearance, inflammation regression, and tissue repair. The interaction of neutrophils with macrophages and other types of cells determines liver immune homeostasis and tissue repair. During viral hepatitis, alcoholic liver disease, metabolic injury, and other conditions, persistent infiltration and multiple dysfunctions of neutrophils usually aggravate liver injury. We will elaborate on this in detail later.

The role of neutrophils in viral hepatitis

A lack of sufficient liver biopsy samples and suitable animal models means that the role of the innate immune system, especially neutrophils, in acute and chronic viral hepatitis is not fully understood. Intrahepatic gene expression profiles show that multiple innate immunity-related genes are inhibited during chronic hepatitis B infection, independent of HBV replication, suggesting that the innate immune response is seriously impaired in patients with chronic HBV infection.13 NETs released by neutrophils are regarded as the main executors of anti-infective and antiviral immunity.14,15 In chronic hepatitis B infection, the amount of NETs decreased and correlated negatively with HBsAg, HBeAg, and HBcAb levels. HBV C protein and HBV E protein might inhibit the release of NETs by inhibiting ROS generation and autophagy, ultimately leading to the delayed elimination of HBV virions.16 In a mouse hepatitis virus-A59 model, excessive NET release by neutrophils was associated with fulminant hepatitis.17 In patients with HBV infection, C-X-C motif chemokine ligand 8 (CXCL8) produced by T cells is the major attractant for neutrophil influx into the liver, which increases the expression of triggering receptor expressed on myeloid cells 1 (TREM1) and aggravates the neutrophil-mediated immunopathology of the liver.18 Meanwhile, the higher neutrophil-to-lymphocyte ratio (NLR) at the 24th week after the onset of interferon treatment predicted the elimination of the replicative HCV-RNA strand in the liver during the antiviral treatment of patients with chronic hepatitis C.19

In a viral hepatitis model induced by lymphocytic choriomeningitis virus infection, deletion of neutrophils increased the viral load, aggravated the T-cell response, and increased liver injury, while IL-33 treatment contributed to reducing liver inflammation by promoting the aggregation and immunosuppressive phenotype transformation of neutrophils within the liver.20 In acute murine viral hepatitis, increased infiltration of neutrophils into liver tissue is also exacerbated by endogenous IL-33 deficiency.21 These data indicated that IL-33 might be a target for reducing neutrophil infiltration in hepatitis, and IL-33 targeting therapy might benefit the outcome of viral hepatitis.

The role of neutrophils in nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), liver cirrhosis, and even liver cancer. Preexisting diseases, including obesity, type 2 diabetes, hyperlipidemia, and insulin resistance, are regarded as the major risk factors for the development of NAFLD.22 Hepatic steatosis is a common consequence of hepatic injury in response to alcohol, toxins, chemotherapy, or metabolic syndrome with insulin resistance and has become the most common liver disease worldwide, including in China.23,24,25 Hepatic steatosis can progress to NASH, which is characterized by inflammation and metabolic disorders. Neutrophil infiltration is associated with liver inflammation and subsequent inflammation-induced pathological injury, which is often caused by dietary carbohydrates and cholesterol and is related to the severity of NASH.22

Human NASH is characterized by hepatic neutrophil infiltration and upregulation of the major neutrophil-recruiting chemokines (CXCL1 and IL-8) in human hepatocytes. However, mice fed a high-fat diet (HFD) only develop a fatty liver without progression to NASH, in which the disparity of p38α (also known as mitogen-activated protein kinase 14 (MAPK14)) activation is an important determinant. Human NASH features strong p38α activation, which induces caspase 3 (CASP3) cleavage, AF4/FMR2 family member 4 (AFF4; also known as CHOP) expression, and BCL2 apoptosis regulator (BCL2) phosphorylation, thereby exacerbating hepatocyte death. However, mice fed a HFD only showed weak p38α activation, which upregulated genes involved in fatty acid β-oxidation that may act to compensate for hepatocyte fat accumulation.26,27 In patients with NASH, serum NET levels are markedly increased. In an animal model of NASH, free fatty acids also stimulated the formation of NETs in vivo and in vitro. Inhibition of NET formation did not affect steatosis but decreased inflammatory cell infiltration and the production of inflammatory cytokines, even slowing down the progression of NASH to liver cancer.28 Serum neutrophil-derived lipocalin 2 is also significantly upregulated in patients with NASH, which triggers C-X-C motif chemokine receptor 2 (CXCR2) expression in an autocrine manner, ultimately promoting neutrophil and macrophage infiltration and aggravating liver inflammation and hepatocyte injury.29 In addition, high neutrophil elastase and low α-1 antitrypsin activities predict the severity of experimental NASH.30 Neutrophils can directly kill hepatocytes by secreting MPO to enhance oxidative stress; indeed, the concentration of MPO in patients with NASH is higher than that in patients with simple steatosis.31 At the same time, MPO can activate hepatic stellate cells and promote liver fibrosis.32 Antibodies against neutrophils improved metabolic syndrome and reduced functional disorders and lipid deposition.33

In short, hepatocyte injury is caused by metabolism and induced by neutrophil infiltration and activation, which in turn mediates hepatocyte injury through ROS, inflammatory mediators, and NETs.34 However, neutrophils do not always play a negative role. High expression of microRNA-223 (miR-223) by neutrophils has immune regulatory functions in a variety of liver diseases. Deletion of miR-223 in a mouse model induced a full range of NAFLD, from simple fatty liver to HCC, combined with increased inflammation.35

The role of neutrophils in alcoholic liver disease

Alcoholic liver disease (ALD) includes a series of disorders from simple fatty liver to alcoholic hepatitis, which can also progress to liver cirrhosis and liver cancer without proper treatment. The pathology of alcohol-related liver injury is very complicated, including the simultaneous occurrence of direct alcohol-related liver injury, dysfunction of the immune inflammatory response to intestinal injury, and microbial translocation. In particular, the unbalanced intestinal bacteria and increased permeability of the gastrointestinal mucosa eventually activate an inflammatory response, induce aseptic necrosis and apoptosis of hepatocytes, and promote neutrophil infiltration, ultimately triggering a series of pathophysiological changes (Fig. 1).36

Fig. 1

Multiple roles of neutrophils in the microenvironment of alcoholic liver disease. Alcohol causes liver damage via acetaldehyde/oxidative stress and endotoxins produced during microbiota translocation. DAMPs and chemokines activate and recruit neutrophils in different ways. On the one hand, hepatocyte injury can be induced by excessive NETs and ROS, and decreased miR-223 promotes IL-6 production, which further contributes to liver injury. The decreased antibacterial ability aggravates infection susceptibility and mortality in advanced liver diseases. On the other hand, neutrophils inhibit liver injury by phagocytosing necrotic cellular debris and secrete hepatocyte growth factor (HGF) to assist hepatocyte regeneration

It is generally accepted that significant neutrophil infiltration into the liver after long-term drinking can also be promoted by drinking heavily over a short period of time. Acute alcohol intake leads to a neutrophil immune imbalance that results in the spontaneous release of NETs. However, the formation of NETs by these neutrophils is decreased upon secondary antigen stimulation and might lead to weakening of the antibacterial ability. Simultaneously, the scavenging effect of macrophages on NETs decreases, resulting in persistent liver inflammation and injury by NETs.37 Extensive oxidative modification of albumin in patients with severe alcoholic hepatitis further activates neutrophils, which induces persistent oxidative stress and inflammation in these patients.38 Blocking neutrophil infiltration using anti-CXCL1 treatments could significantly reduce alcohol-induced liver injury.39

miR-223 is the most abundant microRNA (miRNA) in neutrophils and plays an important role in the modulation of neutrophil function in ethanol-induced mouse liver injury. Elevated serum miR-223 levels were associated with increased infiltration of circulating neutrophils and high levels of alanine transaminase and aspartate transaminase. In addition, miR-223 inhibited IL-6 expression and subsequently inhibited p47phox expression in neutrophils, which alleviated ethanol-induced hepatic injury and ROS production. However, in alcoholic patients, miR-223 in neutrophils was downregulated and IL-6 and p47phox expression were higher than the levels in healthy controls.40 miR-223 could also restore liver inflammation and early fibrosis by inducing the conversion of proinflammatory macrophages to anti-inflammatory types.41 However, in the acetaminophen (APAP) injury model, mitochondrial DNA induces negative feedback activation of miR-223 through Toll-like receptor 9 (TLR-9), which limits the overactivation of neutrophils and liver injury, which might help to reveal the role of neutrophils in ALD.42 Some studies have shown that the combined use of programmed cell death 1 (PD-1) with T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) inhibitors might partially restore the antibacterial ability of neutrophils in patients with alcoholic hepatitis.43 Furthermore, E-selectin binding peptides inhibited the supplementation of neutrophils to inflammatory sites and reduced the levels of proinflammatory factors and chemokines in an alcoholic liver model, which might be used to control liver inflammation.44

Although there have been many reports on the negative roles of neutrophils in alcoholic hepatitis, some clinical studies have drawn different conclusions. On the one hand, the cytokines and chemokines that promote neutrophil infiltration are related to the severity of alcoholic hepatitis by increasing ROS, proteases, and inflammatory mediators, which promote liver inflammation and fibrosis. On the other hand, neutrophils are able to clear necrotic hepatocytes and are an essential source of hepatocyte growth factor (HGF) in patients with severe alcoholic hepatitis, thus participating in hepatocyte regeneration in severe alcoholic hepatitis.45 Moreover, neutrophil dysfunction leads to infection susceptibility and increased mortality in advanced liver diseases. A histological screen identified that the degree of neutrophil infiltration is related to the recovery from acute alcoholic hepatitis and is related to 90-day mortality in patients with alcoholic hepatitis.46 Therefore, the balance of neutrophils between the antibacterial and anti-inflammatory processes needs to be carefully considered in patients with ALD.

The role of neutrophils in liver fibrosis and cirrhosis

Under continuously uncontrolled inflammation and stimulation, apoptosis and pyroptosis of hepatocytes cause serious liver injury, liver fibrosis, or liver cirrhosis. Neutrophils are regarded as important participants that affect the process of liver injury and repair and increase the risk of infection and susceptibility to organ failure at the end stage of liver cirrhosis. During liver cirrhosis, high levels of proinflammatory cytokines, intestinal barrier damage, microflora translocation, portal shunt, circulatory system endotoxins, and the accumulation of other PAMPs contribute to the dysfunction of neutrophils. The overexpression of CD11b (also known as integrin subunit alpha M) and dysfunctional chemotaxis, phagocytosis, degranulation, ROS production, and NET production in neutrophils ultimately lead to deteriorated liver function.47 Simultaneously, stellate cells activated by IL-17+ neutrophils release transforming growth factor beta (TGF-β), resulting in type I collagen deposition and aggravation of fibrosis.48

However, neutrophils also have beneficial roles in liver fibrosis or cirrhosis. A deficiency in MPO release in decompensated alcoholic cirrhosis leads to a decreased antimicrobial ability of neutrophils.45 Meanwhile, neutrophils perform a beneficial function through their production of HGF46 or the promotion of early collagen degradation.49 Coculture of normal neutrophils with plasma from patients with liver cirrhosis caused phenotypic and functional changes similar to those observed in patients with liver cirrhosis, which indicated that the damage might be reversible.50 A retrospective study of patients with liver cirrhosis found that a high NLR was an independent predictor of hospitalization days and 90-day mortality, which was ultimately associated with higher 1-year mortality.51

In patients with decompensated liver cirrhosis, long-term and chronic activation of neutrophils, caused by large amounts of plasma inflammatory substances, leaves them in a state of exhausted fatigue in which neutrophils lose their ability to effectively deal with harmful external substances and show reduced overall anti-infection ability. The increased production of basic neutrophil ROS and deficiency of phagocytic function in these patients are associated with an increased risk of infection, organ dysfunction, and death.47 At present, infection is still one of the leading causes of death in patients with decompensated cirrhosis,52 and the bactericidal deficiency of neutrophils can be reversed by the activation of TLR7/8 in vitro.53 Therefore, both improvement in liver function and control of infection are necessary to improve the final outcomes of patients with liver cirrhosis.

The role of neutrophils in liver failure

During the progression of liver cirrhosis, the immune function of the liver continues to deteriorate, accompanied by portal hypertension, intestinal barrier damage, and bacterial translocation, which might eventually lead to liver failure.54 Liver failure includes acute liver failure, chronic liver failure, subacute liver failure, and acute-on-chronic liver failure (ACLF), which are differentiated according to their pathological features and speed of disease progression.

Acute liver failure represents a unique syndrome of severe injury to liver cells accompanied by altered coagulation and mentation in the absence of chronic liver disease.55 A common cause of death in patients with acute liver failure is systemic complications, which follow the release of proinflammatory cytokines and DAMPs from necrotic hepatocytes, endothelial cells, and leukocytes. Liver transplantation provides a life-saving alternative, and the NLR can be used as a practical index of early graft dysfunction for living donor liver transplantation.56

Paracetamol abuse is the most commonly observed reason for acute liver failure in developed countries. In APAP-induced liver failure, depletion of neutrophils protects against APAP toxicity when given as a 24-h pretreatment.57 The increased blood ammonia contributes to hepatic encephalopathy and could cooperate with endogenous DNA and IL-8 to regulate the expression of TLR-9 on the surface of neutrophils, decrease phagocytic activity, and increase the spontaneous oxidative burst.58 The increased TLR-9 but decreased TLR4 expression on functionally exhausted neutrophils correlates with the degree of encephalopathy.58 Excessive activation of neutrophils during APAP-induced ALF could also increase the susceptibility to sepsis, which might contribute to the high mortality.59 Although the depletion of neutrophils in APAP-induced liver failure models reduces early hepatocyte necrosis, it also dampens hepatocyte regeneration by reducing the levels of matrix metalloproteinases (MMPs);60 therefore, the balance of neutrophils is important to maintain normal liver function.

ACLF is a syndrome that occurs under liver cirrhosis and is characterized by organ failure and a high mortality rate within 28 days.61 During the course of ACLF, both a proinflammatory state and an immunosuppressive state might occur at the same time in which systemic and proinflammatory reactions occur in the early stage and an immunosuppressive reaction follows in the later stage, which manifests as immune paralysis, lymphocytopenia, and secondary infection.62 The state of the immune response depends on the host and the intensity of the pathogens, while the majority of patients with ACLF with liver cirrhosis are in a state of systemic immune exhaustion because of long-term chronic liver disease and tend to lose their normal resistance to infection, which ultimately contributes to liver failure.11 In patients with ACLF, phenotypic and functional changes in neutrophils are generally associated with outcomes. The expression of CXCR1/2 on neutrophils was lower than that in patients with chronic hepatitis, which is linked to the dysfunction of neutrophils and the severity of the disease.59 Blocking CXCR1/2 reduces the production of inflammatory mediators and hepatocyte necrosis.63 NGAL is regarded as a biomarker of ACLF and correlates with liver failure and systemic inflammation.64

The Model for End-Stage Liver Disease (MELD) score is a powerful and effective index to predict the short-term survival of patients with end-stage liver disease. Moreover, the NLR can also be used as an objective parameter to predict prognosis, independent of the MELD and cirrhosis stage. Further studies should highlight the effect of the number and function of neutrophils to optimize the therapeutic regimen used to treat liver failure.65

For patients with HBV-associated ACLF, G-CSF treatment has demonstrated safety and efficacy, which contribute to increasing the liver CD34+ cell and peripheral neutrophil count, reducing the MELD score, avoiding septicemia and new infections, and finally improving overall survival in patients with the disease.66,67,68 Meanwhile, for patients with pediatric ACLF, G-CSF treatment did not demonstrate significant efficacy in improving the outcome69 because ACLF in children can rapidly develop into multiple organ failure. G-CSF is also used to treat advanced liver cirrhosis and severe alcoholic hepatitis in which increased CD34+ cells and neutrophils are also associated with its efficacy (Table 1).

Table 1 Clinical studies of G-CSF for the treatment of liver disease

The role of neutrophils in liver cancer

Unlike other malignant tumors, HCC mainly occurs in a chronic inflammatory environment.70 Neutrophils are found in large quantities and with obvious heterogeneity in the microenvironment of liver cancer. The timely recruitment of neutrophils is controversial in anti-infection and tumorigenesis, showing different functional characteristics after being converted into tumor-associated neutrophils (TANs), which is summarized in Fig. 2. The TANs induced by type I interferon can be polarized to the antitumor N1 phenotype, which has the capacity to kill tumor cells and stimulate T-cell immunity. Meanwhile, the N2 phenotype induced by G-CSF can promote tumor development by inhibiting the T-cell response and upregulating angiogenic factors.71 There is a lack of specific cell surface markers; therefore, these tumor infiltrated neutrophil subsets are mainly classified according to their function and location.72 TANs directly affect tumor cell growth, angiogenesis, and distant metastasis by secreting fibroblast growth factor 2, HGF, oncostatin M, neutrophil elastase, matrix metalloproteinase 9, β2 integrin, and vascular endothelial growth factor (VEGF).73,74 In addition, C–C motif chemokine ligand (CCL) 2 and CCL-17, derived from TANs, indirectly affect the biological characteristics of liver cancer cells, change the tumor microenvironment, and recruit regulatory T cells (Tregs) and macrophages into liver cancer tissue, which boosts the growth and metastasis of HCC.75

Fig. 2

Multiple roles of neutrophils in the microenvironment of hepatocellular carcinoma. Neutrophils have the capacity to inhibit or promote tumor growth dependent on the tumor microenvironment. IL-6- and IL-8-recruited neutrophils kill tumor cells directly via ROS. Tumor cell-derived G-CSF polarizes neutrophils toward a tumorigenesis phenotype, which inhibits T-cell function in a cell–cell contact manner via PD-L1. Tumor-associated neutrophils (TANs) secrete VEGF and MMP-9 to induce angiogenesis, produce FGF2 to promote tumor cell metastasis, secrete CCL-2 and CCL-17 to recruit Treg cells and macrophages that exert immunosuppressive roles, release NETs to promote tumor-related thrombosis, and aggravate the body’s hypercoagulable state

A positive feedback loop of tumor stem cell-like cells and TANs in liver cancer is related to tumor progression. In the tumor microenvironment, TANs promote HCC tumor formation, growth, and metastasis by promoting hepatoma cell proliferation, migration, invasion, colony formation, and the negative regulation of antitumor immunity.76,77,78 Tumor cells secrete CXCL5 and promote the infiltration of more TANs to form a positive feedback loop,78 and overexpression of PD-L1 in TANs contributes to inhibiting the proliferation and activation of T cells.79 TANs can also release NETs to promote the progression of liver cancer,28 induce tumor-related thrombosis, aggravate the body’s hypercoagulable state,80 and increase the risk of tumor-related complications, such as organ failure.81 The tumor growth rate of mice could be slowed down after the deletion of NETs.28 In the animal model, deleting TANs improved the therapeutic effect of sorafenib and reduced drug resistance, which provided important evidence for the clinical use of antitumor drugs.75

The NLR is an independent marker that can be used to predict the disease-free survival rate at 5 years after liver transplantation82 and is also related to the degree of intratumoral macrophage infiltration.83 The recruitment of neutrophils in HCC tissues is related to high levels of TGF-β, receptor tyrosine kinase Axl, and CXCL5.84 In addition, neutrophils can be recruited by self-secreted IL-6 and IL-8, and these cytokines aggravate tumor cell exudation and matrix angiogenesis.72 Neutrophils can also be recruited and polarized by platelets and γδ T cells.85 Hypoxia, nutritional deficiency, and cell necrosis within the tumor lead to the release of DAMPs, which further replenish and activate neutrophils.71

However, the antitumor effect of neutrophils in the tumor microenvironment should not be ignored. Neutrophils induced by tumor necrosis factor alpha have the capacity to slow tumor growth and metastasis through HGF/MET (MET proto-oncogene, receptor tyrosine kinase)-dependent nitric oxide release.86 Meanwhile, TANs can directly kill tumor cells by releasing ROS, stimulating the T-cell response, assisting in antigen presentation, inhibiting early tumor formation, and inhibiting the formation of metastatic foci.87 Although this seemingly contradictory conclusion is caused by the complexity of the biological characteristics of neutrophils, more importantly, it reflects the plasticity of the tumor microenvironment.88 Once the tumor microenvironment is formed, neutrophils are prone to immunosuppression and adopt a tumor-promoting phenotype.


Neutrophil infiltration into the liver is a basic pathological feature of different types of liver disease; however, there are many unanswered issues regarding the kinetics and functions of neutrophils. Neutrophils not only function in anti-infection, immune regulation, tissue repair, and antitumor effects but also cause adverse consequences, including tissue injury, immune paralysis, and promotion of tumor metastasis under the specific tumor microenvironment. In different types and stages of liver diseases, the function of neutrophils may be protective or destructive. Precisely targeting upstream factors or directly affecting the function of neutrophils might become a new direction for the treatment of liver diseases in the future.


  1. 1.

    Xu, R., Huang, H., Zhang, Z. & Wang, F. S. The role of neutrophils in the development of liver diseases. Cell. Mol. Immunol. 11, 224–231 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Xu, Y., Zhang, Q. & Zhao, Y. The functional diversity of neutrophils and clustered polarization of immunity. Cell. Mol. Immunol, (2020).

  3. 3.

    Pillay, J. et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116, 625–627 (2010).

    CAS  PubMed  Google Scholar 

  4. 4.

    Soehnlein, O., Steffens, S., Hidalgo, A. & Weber, C. Neutrophils as protagonists and targets in chronic inflammation. Nat. Rev. Immunol. 17, 248–261 (2017).

    CAS  PubMed  Google Scholar 

  5. 5.

    Heymann, F. & Tacke, F. Immunology in the liver-from homeostasis to disease. Nat. Rev. Gastroenterol. Hepatol. 13, 88–110 (2016).

    CAS  PubMed  Google Scholar 

  6. 6.

    Choudhury, S. R. et al. Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver. Cell 178, 1205–1221 (2019).

    PubMed  Google Scholar 

  7. 7.

    Maianski, N. A., Mul, F. P. J., van Buul, J. D., Roos, D. & Kuijpers, T. W. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 99, 672–679 (2002).

    CAS  PubMed  Google Scholar 

  8. 8.

    Lawrence, S. M., Corriden, R. & Nizet, V. How neutrophils meet their end. Trends Immunol. 41, 531–544 (2020).

    CAS  PubMed  Google Scholar 

  9. 9.

    Zargarian, S. et al. Phosphatidylserine externalization, “necroptotic bodies” release, and phagocytosis during necroptosis. PLoS. Biol. 15, e2002711 (2017).

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Bouchery, T. & Harris, N. Neutrophil-macrophage cooperation and its impact on tissue repair. Immunol. Cell. Biol. 97, 289–298 (2019).

    PubMed  Google Scholar 

  11. 11.

    Bernsmeier, C., van der Merwe, S. & Périanin, A. The innate immune cells in cirrhosis. J. Hepatol. 73, 186–201 (2020).

    CAS  PubMed  Google Scholar 

  12. 12.

    Li, H. et al. Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin-2 and neutrophil extracellular traps. Hepatology 68, 1604–1620 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Lebossé, F. et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J. Hepatol. 66, 897–909 (2017).

    PubMed  Google Scholar 

  14. 14.

    Barr, F. D., Ochsenbauer, C., Wira, C. R. & Rodriguez-Garcia, M. Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal. Immunol. 11, 1420–1428 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Daniel, C. et al. Extracellular DNA traps in inflammation, injury and healing. Nat. Rev. Nephrol. 15, 559–575 (2019).

    CAS  PubMed  Google Scholar 

  16. 16.

    Hu, S. et al. Hepatitis B virus inhibits neutrophil extracellular trap release by modulating reactive oxygen species production and autophagy. J. Immunol. 202, 805–815 (2019).

    CAS  PubMed  Google Scholar 

  17. 17.

    Tang, Y. et al. Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation. J. Hepatol. 68, 733–743 (2018).

    CAS  PubMed  Google Scholar 

  18. 18.

    Kozik, J. H. et al. Attenuated viral hepatitis in Trem1−/− mice is associated with reduced inflammatory activity of neutrophils. Sci. Rep. 6, 28556 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Wróblewska, A., Lorenc, B., Cheba, M., Bielawski, K. P. & Sikorska, K. Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals. Clin. Exp. Med. 19, 401–406 (2019).

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Liang, Y. et al. IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. Cell. Mol. Immunol. 16, 126–137 (2019).

    CAS  PubMed  Google Scholar 

  21. 21.

    Carrière, V. et al. Endogenous IL-33 deficiency exacerbates liver injury and increases hepatic influx of neutrophils in acute murine viral hepatitis. Mediators. Inflamm. 2017, 1359064 (2017).

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Cai, J., Zhang, X. J. & Li, H. The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology 70, 1026–1037 (2019).

    PubMed  Google Scholar 

  23. 23.

    Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Investig. 127, 55–64 (2017).

    PubMed  Google Scholar 

  24. 24.

    Paik, J. M., Golabi, P., Younossi, Y., Mishra, A. & Younossi, Z. M. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatology, (2020).

  25. 25.

    Zhou, J. et al. Epidemiological features of NAFLD From 1999 to 2018 in China. Hepatology 71, 1851–1864 (2020).

    PubMed  Google Scholar 

  26. 26.

    Hwang, S. et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 72, 412–429 (2019).

    Google Scholar 

  27. 27.

    Hwang, S. et al. Protective and detrimental roles of p38α MAPK in different stages of nonalcoholic fatty liver disease. Hepatology, (2020).

  28. 28.

    van der Windt, D. J. et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 68, 1347–1360 (2018).

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ye, D. et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J. Hepatol. 65, 988–997 (2016).

    CAS  PubMed  Google Scholar 

  30. 30.

    Zang, S. et al. Increased ratio of neutrophil elastase to α1-antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis. Clin. Exp. Pharmacol. Physiol. 43, 13–21 (2016).

    CAS  PubMed  Google Scholar 

  31. 31.

    Rensen, S. S. et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am. J. Pathol. 175, 1473–1482 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Pulli, B. et al. Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. Antioxid. Redox Signal. 23, 1255–1269 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Ou, R. et al. Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine 57, 72–82 (2017).

    CAS  PubMed  Google Scholar 

  34. 34.

    Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908–922 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    He, Y. et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology 70, 1150–1167 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Singal, A. K. & Shah, V. H. Current trials and novel therapeutic targets for alcoholic hepatitis. J. Hepatol. 70, 305–313 (2019).

    PubMed  Google Scholar 

  37. 37.

    Bukong, T. N. et al. Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use. J. Hepatol. 69, 1145–1154 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Das, S. et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology 65, 631–646 (2017).

    CAS  PubMed  Google Scholar 

  39. 39.

    Chang, B. et al. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology 62, 1070–1085 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Li, M. et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47-oxidative stress pathway in neutrophils. Gut 66, 705–715 (2017).

    CAS  PubMed  Google Scholar 

  41. 41.

    Calvente, C. J. et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J. Clin. Investig. 130, 4091–4109 (2019).

    Google Scholar 

  42. 42.

    He, Y. et al. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology 66, 220–234 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Markwick, L. J. L. et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 148, 590–602 (2015).

    CAS  PubMed  Google Scholar 

  44. 44.

    Milošević, N. et al. Attenuation of neutrophil-mediated liver injury in mice by drug-free E-selectin binding polymer. J. Control. Release 319, 475–486 (2020).

    PubMed  Google Scholar 

  45. 45.

    Boussif, A. et al. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis. J. Hepatol. 64, 1041–1048 (2016).

    CAS  PubMed  Google Scholar 

  46. 46.

    Taïeb, J. et al. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. J. Hepatol. 36, 342–348 (2002).

    PubMed  Google Scholar 

  47. 47.

    Taylor, N. J. et al. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment. Pharmacol. Ther. 40, 705–715 (2014).

    CAS  PubMed  Google Scholar 

  48. 48.

    Fabre, T. et al. Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis. Sci. Immunol. 3, eaar7754 (2018).

    PubMed  Google Scholar 

  49. 49.

    Harty, M. W. et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am. J. Pathol. 176, 1271–1281 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Mookerjee, R. P. et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 46, 831–840 (2007).

    CAS  PubMed  Google Scholar 

  51. 51.

    Rice, J. et al. Neutrophil-to-lymphocyte ratio associates independently with mortality in hospitalized patients with cirrhosis. Clin. Gastroenterol. Hepatol. 16, 1786–1791 (2018).

    PubMed  Google Scholar 

  52. 52.

    Arvaniti, V. et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139, 1246–1256 (2010).

    PubMed  Google Scholar 

  53. 53.

    Rolas, L. et al. NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation. Gut 67, 1505–1516 (2018).

    CAS  PubMed  Google Scholar 

  54. 54.

    Louvet, A. Restoration of bactericidal activity of neutrophils by myeloperoxidase release: A new perspective for preventing infection in alcoholic cirrhosis. J. Hepatol. 64, 1006–1007 (2016).

    CAS  PubMed  Google Scholar 

  55. 55.

    Stravitz, R. T. & Lee, W. M. Acute liver failure. Lancet 394, 869–881 (2019).

    CAS  PubMed  Google Scholar 

  56. 56.

    Kwon, H. M. et al. Neutrophil-to-lymphocyte ratio is a predictor of early graft dysfunction following living donor liver transplantation. Liver. Int. 39, 1545–1556 (2019).

    CAS  PubMed  Google Scholar 

  57. 57.

    Liu, Z. X., Han, D., Gunawan, B. & Kaplowitz, N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 43, 1220–1230 (2006).

    CAS  PubMed  Google Scholar 

  58. 58.

    Manakkat Vijay, G. K. et al. Neutrophil toll-like receptor 9 expression and the systemic inflammatory response in acetaminophen-induced acute liver failure. Crit. Care. Med. 44, 43–53 (2016).

    CAS  PubMed  Google Scholar 

  59. 59.

    Taylor, N. J. et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology 57, 1142–1152 (2013).

    CAS  PubMed  Google Scholar 

  60. 60.

    Alvarenga, D. M. et al. Paradoxical role of matrix metalloproteinases in liver injury and regeneration after sterile acute hepatic failure. Cells 7, 247 (2018).

    CAS  PubMed Central  Google Scholar 

  61. 61.

    Gustot, T. et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 62, 243–252 (2015).

    PubMed  Google Scholar 

  62. 62.

    Cecconi, M., Evans, L., Levy, M. & Rhodes, A. Sepsis and septic shock. Lancet 392, 75–87 (2018).

    PubMed  Google Scholar 

  63. 63.

    Xu, R. et al. Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure. Sci. Rep. 6, 38714 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Ariza, X. et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J. Hepatol. 65, 57–65 (2016).

    CAS  PubMed  Google Scholar 

  65. 65.

    Kalra, A. et al. Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis. Liver. Transpl. 23, 155–165 (2017).

    PubMed  PubMed Central  Google Scholar 

  66. 66.

    Garg, V. et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 142, 505–512 (2012).

    CAS  PubMed  Google Scholar 

  67. 67.

    Kedarisetty, C. K. et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 148, 1362–1370 (2015).

    CAS  PubMed  Google Scholar 

  68. 68.

    Singh, V. et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am. J. Gastroenterol. 109, 1417–1423 (2014).

    CAS  PubMed  Google Scholar 

  69. 69.

    Sharma, S., Lal, S. B., Sachdeva, M., Bhatia, A. & Varma, N. Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure. J. Clin. Exp. Hepatol. 10, 201–210 (2020).

    PubMed  Google Scholar 

  70. 70.

    Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E. & Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 19, 222–232 (2018).

    CAS  PubMed  Google Scholar 

  71. 71.

    Singel, K. L. & Segal, B. H. Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol. Rev. 273, 329–343 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Giese, M. A., Hind, L. E. & Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 133, 2159–2167 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Engblom, C. et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF neutrophils. Science 358, eaal5081 (2017).

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Gordon-Weeks, A. N. et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice. Hepatology 65, 1920–1935 (2017).

    CAS  PubMed  Google Scholar 

  75. 75.

    Zhou, S.-L. et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 150, 1646–1658 (2016).

    CAS  PubMed  Google Scholar 

  76. 76.

    Park, J. et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016).

    PubMed  PubMed Central  Google Scholar 

  77. 77.

    Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).

    PubMed  PubMed Central  Google Scholar 

  78. 78.

    Zhou, S. L. et al. A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression. Hepatology 70, 1214–1230 (2019).

    CAS  PubMed  Google Scholar 

  79. 79.

    He, G. et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 34, 141 (2015).

    PubMed  PubMed Central  Google Scholar 

  80. 80.

    Wolach, O. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaan8292 (2018).

    PubMed  PubMed Central  Google Scholar 

  81. 81.

    Cedervall, J., Zhang, Y. & Olsson, A. K. Tumor-induced NETosis as a risk factor for metastasis and organ failure. Cancer Res. 76, 4311–4315 (2016).

    CAS  PubMed  Google Scholar 

  82. 82.

    Motomura, T. et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J. Hepatol. 58, 58–64 (2013).

    CAS  PubMed  Google Scholar 

  83. 83.

    Mano, Y. et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann. Surg. 258, 301–305 (2013).

    PubMed  Google Scholar 

  84. 84.

    Haider, C. et al. Transforming growth factor-β and Axl induce CXCL5 and neutrophil recruitment in hepatocellular carcinoma. Hepatology 69, 222–236 (2019).

    CAS  PubMed  Google Scholar 

  85. 85.

    Kim, J. & Bae, J. S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators. Inflamm. 2016, 6058147 (2016).

    PubMed  PubMed Central  Google Scholar 

  86. 86.

    Finisguerra, V. et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522, 349–353 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Németh, T., Sperandio, M. & Mócsai, A. Neutrophils as emerging therapeutic targets. Nat. Rev. Drug. Discov. 19, 253–275 (2020).

    PubMed  Google Scholar 

  88. 88.

    Eruslanov, E. B. et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Investig. 124, 5466–5480 (2014).

    PubMed  Google Scholar 

Download references


The work was supported by grants from the National Science and Technology Fund (Major Project 2018ZX10302104-002) and the National Natural Innovation Fund (Project 81721002).

Author information




K.L and R.X. wrote the manuscript and constructed the figures. F.-S.W. revised the manuscript and figures.

Corresponding authors

Correspondence to Fu-Sheng Wang or Ruonan Xu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, K., Wang, FS. & Xu, R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 18, 38–44 (2021).

Download citation


  • Liver disease
  • Liver injury
  • Neutrophil
  • Innate immunity
  • Immunotherapy

Further reading


Quick links